11/4/11 – Concern Raised After Report Links Pradaxa to Multiple Deaths

  • Home
  • »
  • Blog
  • »
  • 11/4/11 – Concern Raised After Report Links Pradaxa to Multiple Deaths

Concern Raised After Report Links Pradaxa to Multiple Deaths

November 4, 2011 – A recent report has linked multiple deaths to the anticoagulant dabigatran (Pradaxa).  The German article says the deaths were caused by bleeding in atrial fibrillation patients after using the drug which it associated with having “deadly side effects.”

Boehringer Ingelheim, the drug’s manufacturer, responded to the report in a company statement acknowledging, “Serious bleeding events can and do occur, with all anticoagulants including Pradaxa.”  Dabigatran, an oral direct thrombin inhibitor, is approved for stroke prevention in patients with atrial fibrillation in more than 50 countries, including the U.S. and Canada.

Fatalities have occurred in patients taking the blood-thinner Pradaxa.  The anti-clotting pill, like other similar anti-clotting drugs, carries the risk of internal bleeding resulting in death.  No exact number has been confirmed, but at least 50 bleeding deaths have been associated with the defective drug Pradaxa.

ThePhiladelphia personal injury attorneys at Messa & Associates are experienced at handling cases involving pharmaceutical and drug product injuries.  Our skilled team of attorneys has successfully pursued litigation and obtained verdicts and settlements for victims of pharmaceutical injuries.  If you or a loved one has suffered serious injury or death as a result of the anticoagulant Pradaxa, please contact us at 1-877-MessaLaw.


Call the Philadelphia personal injury lawyers of Messa & Associates today to discuss your case with a professional who has the knowledge to answer your questions or submit a free online inquiry.

Call, toll-free, 1-877-MessaLaw (637-7252), or submit a free online inquiry form.

About the Author:

Director of Marketing for Messa & Associates located in Philadelphia, Pennsylvania. For all marketing or press release communications, contact sking@messalaw.com.

Leave a Reply

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}